Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers ...Middle East

SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines...

Hence then, the article about antengene announces claudin 18 2 antibody drug conjugate atg 022 granted orphan drug designations by the u s fda for the treatment of gastric and pancreatic cancers was published today ( Tuesday 23/05/2023 - 12:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers )

Also on site :

• Travel Warning Issued For Millions Across US
• ‘Change is inevitable’: What is next for Iran?
• Australian Open: Sinner overcomes cramps; Keys, Pegula advance; Osaka withdraws